Four CYP19A1 Polymorphisms and Breast Cancer Risk: A MetaAnalysis
Many molecular epidemiological studies have investigated an association between CYP19A1 gene single-nucleotide polymorphisms (SNPs) and breast cancer risk, but results have remained controversial and inconclusive. In order to reveal the real association, we performed an updated meta-analysis including two CYP19A1 gene polymorphisms (rs700519, rs10046). Moreover, we performed a meta-analysis of another two CYP19A1 (rs2236722 and rs4646) gene polymorphisms for the first time to evaluate their relevance in susceptibility to breast cancer risk. A systematic database search was conducted to retrieve eligible articles. The odds ratio (OR) with 95% confidence interval (95% CI) were used to assess the strength of the association.A total of 38 eligible studies were included in the meta-analysis, and the results showed that three CYP19A1 gene polymorphisms (rs700519, rs10046, and rs2236722) had no relationship with an increased/decreased breast cancer risk in overall or ethnicity-based populations (all P values were more than 0.05); CYP19A1 rs4646 polymorphism was significant associated with an increased breast
cancer risk in overall populations under dominant genetic model (CC+AC vs. AA, OR=1.179, 95% CI=1.056 - 1.315, P-value=0.003). However, we did not find an association between CYP19A1 rs4646 polymorphism and breast cancer susceptibility among Asian populations (P value was more than 0.05).The meta-analysis indicates that CYP19A1 rs4646 polymorphism may be associated with breast cancer risk. Further epidemiological studies with larger sample sizes are needed to validate the association between CYP19A1 rs4646 polymorphism and breast cancer risk in various populations.